NovaBay Pharma Receives a Buy from Roth Capital

By Ryan Adsit

In a report issued on June 23, Scott Henry from Roth Capital reiterated a Buy rating on NovaBay Pharma (NYSE: NBY), with a price target of $5.50. The company’s shares opened today at $3.65.

According to TipRanks.com, Henry is a 3-star analyst with an average return of 1.0% and a 42.7% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Synergy Pharmaceuticals Inc, and Avadel Pharmaceuticals plc.

NovaBay Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

The company has a one year high of $5.29 and a one year low of $2.12. Currently, NovaBay Pharma has an average volume of 16.31K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing products for the eye care.